This Trial is Conducted in Europe. The Aim of This Trial is to Investigate Pharmacodynamics (the Effect of the Investigated Drug on the Body) , Pharmacokinetics (the Exposure of the Trial Drug in the Body), and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2017
At a glance
- Drugs NN 1406 (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novo Nordisk
- 18 Aug 2017 Status changed from active, no longer recruiting to completed.
- 24 May 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Oct 2016 New trial record